Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MF101
- Development stage
- Phase 3
- Lead developer
- Bionovo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MF101 is an oral drug designed for the treatment of menopausal vasomotor symptoms (hot flashes and night sweats) in peri-menopausal and menopausal women. It is a selective estrogen receptor beta (ERβ) agonist that does not activate estrogen receptor alpha (ERα), which is associated with increased risk of breast and uterine cancers. The active ingredients in MF101 are derived from botanicals with centuries of recorded safe, effective use in traditional Chinese medicine (TCM). In clinical trials, the 10 g/day dose showed efficacy in reducing the frequency of hot flashes.
- Brand names
- Menerba
- Other names
- Menopause Formula 101
02
Targets
ESR2 (ERβ)
Beyond the preview
Go deeper on MF101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MF101.